NCT02003144 2022-08-23An Open Label Extension Trial of Eculizumab in Relapsing NMO PatientsAlexion Pharmaceuticals, Inc.Phase 3 Completed119 enrolled 17 charts
NCT01892345 2019-06-26A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)Alexion Pharmaceuticals, Inc.Phase 3 Terminated143 enrolled 18 charts
NCT00004645 2005-06-24Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous MethylprednisoloneOffice of Rare Diseases (ORD)Phase 3 Unknown22 enrolled